细胞免疫治疗联合含硼替佐米化疗方案治疗多发性骨髓瘤效果分析  

Immunotherapy combined with bortezomib for multiple myeloma

作　　者：侯开娟[1] 

机构地区：[1]莱州市人民医院血液科,261400

出　　处：《国际医药卫生导报》2016年第6期804-807,共4页International Medicine and Health Guidance News

摘　　要：目的探讨细胞免疫治疗联合含硼替佐米的化疗方案治疗多发性骨髓瘤的效果。方法收集本院2011年1月至2015年1月收治的多发性骨髓瘤患者50例进行前瞻性研究且随机分为对照组与实验组，每组25例。对照组给予含硼替佐米化疗治疗，实验组则加施细胞免疫治疗，比较两组整体治疗效果、相关临床指标与不良反应情况。结果实验组治疗总有效率明显高于对照组，差异有统计学意义（P〈0．05）；HB、Ph、白蛋白、球蛋白、血沉与骨髓浆细胞等指标，实验组治疗前、后组内比较，差异有统计学意义（P〈0．01）；两组治疗后各指标组间比较，差异有统计学意义（P〈0．01）；两组血液学毒性、肝损伤、感染、心脏毒性、外周神经毒性与消化道反应情况差异无统计学意义（P〉0．05）。结论细胞免疫治疗联合含硼替佐米化疗方案治疗多发性骨髓瘤疗效显著，且安全性较高，具有借鉴性。Objective To investigate the effect of cellular immune therapy combined with bortezomib for multiple myeloma. Methods 50 patients with multiple myeloma treaded at our hospital from January, 2011 to January, 2015 were collected and randomly divided into a control group and an experimental group, 25 for each group. The control group were treated with bortezomib-chemotherapy; and in addition, the experimental group were treated with immunotherapy. The overall treatment effect, related clinical indicators, and the incidence of adverse reactions were compared between these two groups. Results The total efficacy was significantly higher in the experimental group than in the control group, with a statistical difference （P〈0.05）. The levels of HB, Plt,albumin, and globulin, ESR, bone marrow plasma cells, and other indicators were better after than before the treatment in the experimental group, with statistical differences （P〈0.01）, and were better in the experimental group than in the control group after the treatment, with statistical differences （P〈0.01）. There were no statistical differences in the incidences of blood toxicity, liver damage, infection, cardiac toxicity, peripheral neurotoxicity, and gastrointestinal reactions between these two groups （P〉 0.05）. Conclusions Immunotherapy combined with bortezomib for multiple myeloma is significantly effective and safe and is of reference.

关 键 词：细胞免疫法 硼替佐米 化疗 多发性骨髓瘤 治疗效果 不良反应 

分 类 号：R730.51[医药卫生—肿瘤]